STOCKS TELEGRAPH

Tag: LIAN

  • Biotech LianBio (LIAN) to Cease Operations, Brings on Premarket Plummet

    LianBio (NASDAQ: LIAN) experienced an unexpected plummet in premarket trading, plunging by nearly 96%, with recent grim announcements. The company’s shares, which had sluggishly climbed merely by 0.81% on Thursday, witnessed a drastic fall in premarket hours, leaving investors bewildered.

    Just over a month ago, LianBio, a prominent Chinese biotech firm, conceded to the inevitable, declaring a conclusive end to its operations after a comprehensive four-month strategic review. Despite this decision looming, the company’s stock demonstrated a curious ascent, rising by 3% over the past month.

    A Rough History

    The departure of LianBio’s CEO and CFO in December 2023 foreshadowed a turbulent trajectory for the biotech, further accentuated by the rejection of a buyout proposal from Concentra Biosciences. Opting against the acquisition bid, LianBio took a definitive step towards winding down operations, concurrently initiating asset liquidation proceedings.

    This decisive move, announced last month, aims to expedite the dissolution process, anticipating completion by the end of the year, though the final dissolution is anticipated closer to 2027.

    Evidently, LianBio has been progressively divesting its assets, relinquishing rights to significant pharmaceuticals such as mavacamten and NBTXR3 to industry giants Bristol Myers Squibb and Johnson & Johnson, respectively. The impending staff reductions, with 50 full-time positions set to be axed by the end of March, signify the gravity of the company’s decision.

    Prioritizing Shareholder Interests

    In a proactive bid to uphold shareholder interests, LianBio plans to distribute proceeds from asset sales and extend a special cash dividend totaling $528 million to its American depository share holders. Notwithstanding these measures, the company cautions against expecting full recovery of investments, reflecting the precarious financial landscape it navigates.

    The abrupt denouement of LianBio, once poised to carve a niche in the biopharmaceutical landscape, underscores the capricious nature of the sector. Amidst a backdrop of failed buyout overtures and executive exodus, the decision to wind down operations reverberates through the market, prompting analysts to scrutinize the implications for the broader biotech industry.

    Conclusion

    With the lingering uncertainties, bearish sentiments persist, anchored on the belief that LianBio’s current valuation remains below its potential liquidation worth, hinting at no opportunities amid the tumultuous market landscape. Overall, it seems that the bears believe there is no gain to be made from the LIAN stock.

  • LianBio (LIAN) Stock Is On The Rise Today: What’s Driving It?

    LianBio (LIAN) Stock Is On The Rise Today: What’s Driving It?

    LianBio (NASDAQ: LIAN) stock has exhibited a notable ascent on the financial charts during the early trading hours. In the morning session, the LianBio stock recorded a significant surge of 79.14%, reaching a value of $2.49 at the most recent assessment. It is worth noting that during the preceding trading session, the LIAN stock witnessed a modest decline of 2.11%, ultimately settling at $1.39. This notable upswing in LIAN stock is the result of a noteworthy development – the company’s entrance into a strategic alliance.

    Today, LianBio (LIAN) formalized a significant agreement with Bristol Myers Squibb (BMS). In accordance with the terms of this pact, BMS has been granted exclusive rights by LianBio to spearhead the development and commercialization of mavacamten within the confines of Mainland China, Hong Kong, Macau, Taiwan, Singapore, and Thailand.

    This agreement marks a transition from the exclusive license agreement that LianBio had previously entered into with MyoKardia, Inc., now a wholly-owned subsidiary of BMS, back in August 2020, in pursuit of these very rights. As per the stipulations outlined in the agreement, LIAN is set to receive a one-time payment of $350 million.

    Furthermore, LianBio will be absolved from its financial commitments, which could have amounted to as much as $127.5 million in pending milestone payments under the MyoKardia license agreement. In April 2023, the China National Medical Products Administration (NMPA) accorded Priority Review status to a New Drug Application (NDA) for mavacamten.

    The NDA was intended for the treatment of adults afflicted by symptomatic obstructive hypertrophic cardiomyopathy (oHCM). LianBio had already secured approvals for mavacamten for the treatment of symptomatic oHCM in Macau and Singapore earlier in 2023.

    The LIAN team successfully executed a meticulous clinical development and regulatory strategy within its designated regions, and has judiciously established a robust infrastructure in anticipation of the potential approval of mavacamten in China in the forthcoming year.

    With BMS taking the helm as the global owner, the company is ideally poised to further enhance the value created by LianBio for mavacamten in China and enhance patient access to this vital new therapeutic offering across the specified territories. BMS also has plans to extend employment offers to select LianBio personnel who have been actively engaged in the development and commercialization of mavacamten.

    In tandem with this transaction, the Board of Directors at LianBio has initiated a comprehensive strategic evaluation of the company’s trajectory. The LianBio Board of Directors anticipates furnishing an update on the results of this strategic review in the first half of 2024.